Waldman Professor News Today

The NIH has awarded Emma Guttman-Yassky, MD, PhD, a $6.6 million grant to investigate dupilumab as a treatment for children with alopecia areata, Mount Sinai announced in a press release. “There is a huge unmet need still in alopecia areata (AA) for targeted treatments, but the one population that the need is much bigger for than anyone else is children,” Emma Guttman-Yassky MD, PhD,

These findings are the first to characterize the unique molecular profile of seborrheic dermatitis...

09.03.2024 - Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signatureSuggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern SAN DIEGO, Calif., March 09, ... Seite 1

The Mount Sinai-Clinique Healthy Skin Dermatology Center ‘aims to uncover scientific findings’ to ‘help alleviate allergic skin conditions,’ and its ‘priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin,’ said Michelle Freyre, President, Global Brands, Clinique and Origins, at The Estée Lauder Companies.

Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount SinaiClinique Healthy Skin Dermatology Center.

New Research Center Aims to Deliver Breakthrough Advancements in Dermatology and Discover Solutions for Healthy and Allergic Skin ...

Andrew L. Ji, MD, is working to better understand cutaneous squamous cell carcinoma —a skin cancer that is the second most common cancer in the United States and one that causes substantial morbidity, with a considerable risk for metastatic spread and death.

First readout of two-year data from long-term extension study INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with...

This new data had both a consistent long-term safety and tolerability profile with the previous short-term results for the skin disease, and there were no new safety signals recorded.

Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.